Objective: Prior studies on the cause and effect of surgical variation have been limited by utilization of administrative data. The Vascular Quality Initiative (VQI), a robust national clinical registry, provides anatomic and perioperative details allowing a more robust analysis of variation in surgical practice.
In the current healthcare climate, there is an increasing emphasis on efficient resource utilization while simultaneously optimizing outcomes. Variation in surgical practice has been discussed in this context as both a reason for inefficient resource utilization and cause of suboptimal outcomes. 1 The Dartmouth Atlas project estimates that 20%-30% of the nation's healthcare spending adds no increased benefit to outcomes and is, therefore, unnecessary. 2 In an attempt to understand surgical variation Birkmeyer et al 1, 3 proposed five categories to explain variation in surgical care; patient demand/disease burden, physician beliefs on indication for a given procedure, patient preferences, regionalized practice patterns, and environmental factors (which include availability and advancements in technology, financial incentives, supply of surgeons, etc.). The Society for Vascular Surgery (SVS), in an attempt to reduce variation where strong evidence exists, has produced multiple consensus statements for the management of vascular disease. [4] [5] [6] [7] From The SVS created the Vascular Quality Initiative (VQI), with prospective collection of detailed clinical data on common vascular procedures with a goal of improving patient care. [8] [9] [10] One major opportunity for improving care is to initially determine and subsequently disseminate best practices for vascular surgical care and subsequent dissemination of information. The TransAtlantic Inter-Society Consensus (TASC) and the American Heart Association (AHA) have produced similar guidelines and consensus statements to reduce variation in care. 11, 12 The federal government, through the Affordable Care Act, established the Patient Centered Outcomes Research Institute to improve patient care through the identification of best practices, with respect to patientcentered outcomes, and has been given a budget of approximately $3.6 billion over 10 years. The treatment of peripheral artery disease (PAD) has undergone rapid expansion, in available procedures and interventions performed, with the incorporation of endovascular techniques. 13 The resulting variation in surgical care for PAD has been a topic of national concern, with a recent New York Times article citing the potential overuse of endovascular therapy for PAD in the Medicare population, and demonstrates the need to address variation in surgical practice for PAD. 14 The SVS has produced consensus statements for guidelines on appropriate treatment of PAD, but as prior work has demonstrated, this does not always result in adherence to such guidelines and the subsequent presumed reduction in variation of surgical practice.
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The purpose of this study is to describe the regional variation that currently exists for the treatment of PAD with respect to patient selection, treatment, and process measures.
METHODS
Dataset. We used the VQI database to identify all infrainguinal bypass procedures and endovascular interventions from participating hospitals across the United States, from 2009 to 2014. The VQI is a national clinical registry, set up as a collaboration between regional quality groups in an effort to improve patient care through the collection of clinical data, and includes 16 regions and close to 300 participating hospitals with 1300 physicians. More information about the VQI can be found at www.vascularqualityinitiative.org/. The Beth Israel Deaconess Medical Center Institutional Review Board approved this study and waived patient consent because of the deidentified nature of the data.
Cohorts and variables. All patients undergoing infrainguinal bypass or endovascular intervention below the infrainguinal ligament were selected from 2009 to 2014. Patients were excluded if their symptom status was missing. Data were stratified by symptoms, intervention type, and region. Chronic limb-threatening ischemia (CLI) was defined as rest pain or tissue loss and acute limb-threatening ischemia (ALI) was considered separately. Medians reported are at the regional level to not be skewed by regions that contribute more cases.
Analysis and figures. Forest plots were used to demonstrate regional variability with each repeating symbol along a line representing an individual region and a perpendicular vertical line representing the VQI median. Bar charts were used to display the relationship of paired variables by region arranged from low to high for one of the paired variables. The data were stratified by symptom status, claudication vs CLI, and type of intervention (bypass vs endovascular). All variables analyzed had <5% missing data with the exception of skin preparation (7% missing) and operative time (7%) for bypass and TASC class (12%) and fluoroscopy time (7%) for endovascular interventions. Variation between regions was assessed by c 2 analysis, with P value of <.05 considered statistically significant. All analyses were performed using SPSS v 22.0 (IBM Inc, Chicago, Ill).
RESULTS
A total of 52,373 interventions were identified (31% open and 69% endovascular). For bypass, 2% of patients were excluded for missing documentation of symptom status. Of the remaining 16,145 bypasses, 5% were performed for asymptomatic PAD. Of these, 54% were for aneurysmal disease, 17% for occlusive disease (of whom 31% had prior bypass), and 29% for unknown pathology (of whom 14% had prior bypass). Of the remaining patients, 26% for claudication, 56% for CLI (61% of these for tissue loss), and 13% for ALI. The range for regional procedure volume over the study period ranged widely from 124 to 5573 bypasses per region.
For endovascular procedures, 2% were excluded for having no recorded symptom status. Of the 35,338 remaining endovascular interventions, 4% were for no symptoms. Of these 19% were for aneurysmal disease, 58% for occlusive disease (of whom 35% had prior bypass), and 23% for unknown pathology (of whom 11% had prior bypass). Of the remaining patients, 40% for claudication, 44% for CLI (73% of these for tissue loss), and 12% for ALI. The range for regional procedure volume ranged from 412 to 7545. Fig 1, A shows the baseline characteristics of patients with claudication who underwent bypass or endovascular revascularization, and Fig 1, B shows the same characteristics for those with CLI. For both bypass and endovascular interventions, there was significant variation in the proportion of octogenarians being treated for claudication (bypass: regional range, 3.2%-14%; P < .001; endovascular: 8.7%-24%; P < .001) and CLI (bypass: 9.0%-22%; P < .001; endovascular: 14%-27%; P < .001) and women being treated for claudication (bypass: 20%-35%; P < .001; endovascular: 32%-46%; P < .001) and for CLI in the endovascular group (38%-47%; P < .001). There was variation in the proportion of females treated by bypass but this did not reach significance (bypass: 27%-41%; P ¼ .23). There was also large variation in the proportion of nonwhite patients being treated regardless of symptom status across both bypass and endovascular interventions. Common comorbidities in this population, such as diabetes mellitus, coronary artery disease, congestive heart failure, and chronic obstructive pulmonary disease, also showed significant variation within each treatment type for patients with both claudication and CLI.
There was significant variation in prior ipsilateral procedures in the bypass group for patients with claudication (inflow bypass: 4%-15%; P < .001; inflow percutaneous transluminal angioplasty (PTA)/stent: 5%-19%; P < .001; outflow bypass: 4%-20%; P < .001; outflow PTA/stent; 17%-33%; P < .001) and CLI (inflow bypass: 2%-10%; P < .001; inflow PTA/stent: 10%-20%; P < .001; outflow bypass: 9%-26%; P < .001; outflow PTA/stent: 21%-37%; P < .001).
Fig 2 demonstrates significant variation across all preoperative imaging modalities and in particular for preoperative vein mapping (claudication: 28%-68%; P < .001; CLI: 40%-84%; P < .001).
The proportion treated for CLI compared with claudication varied significantly across regions for both bypass (38%-71%; P < .001) and endovascular interventions (28%-63%; P < .001; Fig 3) . Among patients with CLI, tissue loss was more common than rest pain for both characteristics for claudication (A) and chronic limb-threatening ischemia (CLI) (B) by intervention type. Diabetes includes both insulin and noninsulin dependent. All variation was significant (P < .001) except that denoted by an asterisk (*). Each symbol on a line represents a region with a vertical line for the region-level median. CAD, Coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease.
bypass and endovascular interventions (61% and 73%, respectively) but was also significantly variable across regions (bypass: 51%-68%; P < .001; endovascular: 65%-84%; P < .001). There was also a wide range of patients undergoing treatment for ALI (bypass: 5%-25%; P < .001; endovascular: 3%-23%; P < .001) and asymptomatic disease without lower extremity aneurysms (bypass: 0.6%-5%; P < .001; endovascular: 2%-10%; P < .001).
There was wide variation in regional utilization of endovascular intervention (vs bypass) to treat claudication, ranging from 68% to 90%, and CLI, ranging from 44% to 77%. There were also differences in proportion of nonelective cases presenting for CLI (bypass: 6%-52%; P < .001; endovascular: 1%-60%; P < .001). A large percentage of patients with claudication were treated with prosthetic conduits vs vein for bypass (36%-56%; P < .001), with 14% of these patients undergoing re-do bypass. Similarly, there was a high proportion treated with prosthetic conduit vs vein for distal bypass, defined as below-knee popliteal or more distal target, in patients with claudication (13%-41%; P < .001), 23% of whom were undergoing a redo bypass, and CLI (14%-30%; P < .001; Fig 4) . During endovascular interventions infrapopliteal stents, vs angioplasty alone, were used at a significantly variable rate for patients with claudication (0%-18%; P < .001) and CLI (0%-25%; P < .001). There was also significant variation in proportion of TASC-D lesions treated out of total tibial endovascular interventions (claudication: 6.6%-47%; P < .001; CLI: 12%-59%; P < .001) and utilization of closure devices after any percutaneous intervention (claudication: 26%-76%; P < .001; CLI: 30%-78%; P < .001). endovascular interventions, respectively. There was significant variation in single-vessel (vs multivessel) endovascular intervention across regions for patients with claudication (44%-71%; P < .001) and CLI (33%-57%; P < .001). The proportion of isolated tibial endovascular interventions, out of all endovascular interventions, for claudication was low but still significantly varied across regions (0%-5%; P < .001).
Fig 6, A and B illustrate the proportions of patients on any antiplatelet agent and a statin, on dual antiplatelet therapy, and on anticoagulation, at admission and discharge. The discharge medication proportions excluded patients who were noncompliant or not able to take one of the medications for medical reasons. Although many regions met the SVS's suggested goal of having 80% of postoperative vascular patients discharged on an antiplatelet and statin medication, there was substantial variation and the median fell below 80%. Notably, no region met that standard in the endovascular-treated CLI cohort (56%-75%; P < .001). There was significant variation among all stratified groups for patients discharged on dual antiplatelet therapy, which was more commonly prescribed after endovascular intervention.
Several additional process measures with accumulating data warrant analysis (Fig 7) . Chlorhexidinebased preparation solutions were used in 86% of claudication (62%-98%; P < .001) and 90% of patients with CLI (52%-96%; P < .001). Ultrasound guidance for percutaneous access showed considerable variation (claudication: 7%-60%; P < .001; CLI: 5%-64%; P < .001). Other potential quality metrics, with significant variation, include prolonged operative time (>220 minutes) in bypasses for claudication and prolonged fluoroscopy time (>50 minutes) during any endovascular intervention for PAD.
DISCUSSION
By illustrating the variation that exists in lower extremity vascular surgical care across the VQI, this descriptive study serves a two-fold purpose. First, it highlights the amount of variation in selection and treatment of this population, and second, it helps divide the data into potentially unwarranted variation and variation of unknown significance.
Currently, there are a number of clinical areas where clear guidelines exist, from both the SVS and the AHA, and yet our study finds continued variation across regions (Table) . 7, 11, 12 We suggest this variation is unwarranted and believe quality efforts should focus on education about and adherence to already established best practices. Practice patterns that have strong enough evidence to expect more uniform practice include antiplatelet and statin medications at discharge and use of chlorhexidine preparation solutions for bypass. [16] [17] [18] Our analysis showed significant variation within these measures over the study period. It should be noted that much of the evidence supporting the above factors came after the initiation of our study period, and this could be leading to some of the variation we report. In addition, we do not know what percent of providers were aware of these guidelines. However, we know that historically there has been slow acceptance of guidelines and benchmarks set by professional societies, and, therefore, we believe much of the variation within this group reflects the most current practice. 3, 19 Facilitators associated with improved uptake of guidelines have been identified in the process for creation of guideline content and how effectively and efficiently that content is communicated to its audience. 20 Creation of content begins with involvement of stakeholders and also includes appropriate synthesis of evidence, clinical relevance, and implementation feasibility, including associated resources and costs. Unwarranted variation also includes clinically relevant variation from zero for "almost never events" that should occur at a zero or exceedingly low rate. Examples of events that should be very low or never occur include isolated tibial angioplasty or below-knee stenting for claudication, and endovascular intervention of the profunda femoris artery for claudication. 7, 12 Within this category, it is also important to highlight the proportion of patients undergoing both bypass and endovascular intervention for asymptomatic PAD with no documented aneurysmal disease. The SVS guidelines have recommended against treatment of asymptomatic disease in general given its unclear benefit. 7, 12 From the data available, we could not discern why exactly these asymptomatic patients underwent intervention and had no way of verifying the symptom status was accurate. The SVS guidelines have also recommended against intervention on isolated infrapopliteal artery lesions for claudication. 7 Use of prosthetic conduit for below-knee bypass in patients with claudication should be minimized given its
Fig 5. Proportion of target vessels for bypass (A) and most distal vessel treated for endovascular intervention (B).
Above-knee includes common femoral artery (CFA), superficial femoral artery (SFA), profunda, and above-knee popliteal. Tibial defined as tibioperoneal trunk, anterior tibial, posterior tibial, and peroneal. Endovascularpopliteal intervention not stratified to above-or below-knee. BK, Below-knee; CLI, chronic limb-threatening ischemia; Pedal, dorsalis pedal, posterior tibial at ankle level, and tarsal/plantar. inferior long-term performance compared with vein, but our analysis showed significant variation with some regions reaching over 40% of such cases being performed. 7 Possible reasons for the persistence of such practice variation include reluctance to change practice pattern, other environmental influences on treatment strategy, or unique clinical presentations poorly captured in the registry database that do warrant such interventions. We believe there is also an intermediate category of potentially unwarranted variation where data are mounting and regions may want to consider whether adequate data exist or if more should be collected and analyzed. For example, routine ultrasound scan use for percutaneous endovascular intervention has been shown to reduce access complications in both single-center and regional level studies and is now being analyzed at the national level. 21, 22 It is difficult to identify unwarranted variation in areas of clinical ambiguity, where no consensus on best treatment exists; however, wide variation suggests an Preoperative anticoagulation only for years 2012-2014 because of reporting of this variable. All variation was significant (P < .001). CLI, Chronic limb-threatening ischemia; DAPT, dual antiplatelet therapy. opportunity for further evaluation and possible quality improvement. In terms of patient selection, there is evidence that disease burden varies by region, but prior work focusing on regional variation has also found that regional differences in comorbidities only account for a small proportion of variation in who gets surgery and who does not, and the decision to operate may be more related to where a patient lives rather than patient-level factors that make the analysis of surgical practice patterns that much more imperative. 1, 23 Related to a surgeons' belief in appropriate threshold for intervention, preoperative imaging behaviors can directly affect rates of intervention. This has been shown in the cardiac literature where rates of coronary intervention (both percutaneous coronary intervention and coronary artery bypass graft) were found to be directly proportional to rates of cardiac catheterization. 24 There have been no clear guidelines on the preoperative imaging modality of choice, as discussed in the SVS and AHA guidelines, and this lack of clarity was reflected in the variation seen in our analysis. 7, 12 We hypothesize that much of this variation is a result of hospital or provider preference. Furthermore, we cannot verify if all this imaging was done prior to making the decision to intervene, which may also affect choice of modality. However, identifying the best imaging modality (or sequence of imaging) for a particular disease process may have a large impact on patient care. Further, there is already general agreement that vein mapping should be performed for any patient being considered for bypass and the variation seen in our analysis suggests that this is not the case; however, the VQI does not collect data on prior harvest or presence of arteriovenous fistula and may miss vein-mapping performed by the surgeon outside of the vascular laboratory without official documentation of this testing. 7, 25 In terms of procedure indication, it remains unclear what the appropriate proportion of claudication to patients with CLI should be for a given region, and whether this is even a value that can be established, however, outlier regions in either direction from our study may be over or undertreating those with claudication. Reasons for the development of practice patterns that disproportionately treat claudication or CLI within the VQI are likely multifactorial and could include patient preference, provider belief in appropriate indication for an intervention, timing of referral, financial incentives, availability of vascular specialists, or teaching paradigm under which these specialists were trained. 1, 3, 23 The VQI is incorporating the Wound, Ischemia, and foot Infection (WIfI) classification schema into the registry moving forward to help better define disease severity at time of intervention and may help better elucidate how much variation actually exists in terms of threshold for intervention. 26 Similarly, it is unclear what is an appropriate proportion of octogenarians undergoing revascularization. Older age has been a strong risk factor for adverse events historically, but more recent data, focusing on endovascular interventions, have pointed toward acceptable common end points in this population. [27] [28] [29] [30] Within the VQI there were a larger proportion of patients with CLI who underwent bypass compared with those with claudication, which was in line with the AHA practice guidelines for PAD that recommends surgical bypass in more extensive peripheral vascular disease. 12 The low rate of tibial/pedal bypass compared with endovascular interventions is concerning due to the questionable long-term durability of these endovascular interventions, although the ongoing Best Endovascular vs Best Surgical Therapy (BEST) CLI randomized controlled trial is trying to conclusively answer this question of treatment choice. 11 Recent data from the Board of Process measures for bypass and endovascular intervention. All variation was significant (P < .001). CLI, Chronic limb-threatening ischemia; US, ultrasound.
Vascular Surgery suggest that many graduating vascular fellows are not adequately trained in performance of tibial or pedal bypass, which could serve to exacerbate this pattern. 31 In addition to the more established process measures discussed above, we propose additional quality metrics, including prolonged operative and fluoroscopy time (as a surrogate for total fluoroscopy dose) for bypass and endoscopic interventions, respectively. Operative time greater than 220 minutes in bypass for claudication warrants consideration because of its demonstrated increase in surgical site infection rates and hospital length of stay. 32 Similarly, increasing radiation doses, for which fluoroscopy time can be used as an indirect measure, has been associated with higher risk of radiation-induced skin damage. 33 However, we recognize that measures of total radiation dose, and not fluoroscopy time, would be optimal and, therefore, we suggest that tracking of this metric should be incorporated into clinical registries.
Medical management of PAD is another area of potential quality improvement. There has been recent evidence that dual antiplatelet therapy in patients undergoing lower extremity revascularization may improve short-term patency and have long-term benefits, compared with monotherapy, and our data showed there was use of dual antiplatelet therapy, although additional cardiac indications for such a regimen also exist and were not controlled for in our analysis. 34 The VQI, with its participating regional quality groups, has a structure to help identify best practice, though identifying high performers in established quality metrics, and an administrative body in place to disseminate information and promote adherence to guidelines. The VQI has adopted a reporting system comparing "your hospital" to peers in the region as well as nation, in addition to risk-adjusted outcomes to help hospitals compare themselves. We believe this internally driven, self-monitored approach has high buy-in from participating centers, and early efforts have shown it to be effective in changing practice, as reported for bovine patch use and protamine administration in the Vascular Study Group of New England. 35, 36 Future analyses focused on adherence rates to new guidelines will need to factor in the confounding effect of the addition of new hospitals to the VQI. This study has several limitations. Most notably, it is a retrospective analysis of a prospectively collected database and has potential issues of miscoding and misreporting. However, the VQI conducts annual audits to ensure consecutive procedure entry and to eliminate any inconsistencies between claims data and clinical data entered by each hospital. The centers and regions are also deidentified and, therefore, have no benefit from misreporting. As VQI is a growing registry, some regions' low volumes for particular procedures may be more a reflection of fewer participating hospitals and not reflect true volume in the region. Statistical testing was used to assess if the variation across all regions differed significantly and does not actually identify those particular regions that lead to the significant difference. In addition, our data are unadjusted and, furthermore, do not account for the geographic reasons for variation based on disease burden. Also, in subset analyses we lose significance for variation in certain variables, despite a wide range, because of limited sample size, and, thus, there may still be room for quality improvement projects even in areas where variation was not significantly different. However, the purpose of this analysis is to be descriptive and not to make assumptions about quality of care in a particular region based on our data alone. In addition, the lack of adjustment allows for comparison with SVS guidelines, which also do not adjust for patient demographics. Another important limitation is that patients managed nonoperatively for PAD are not currently represented in the VQI, and additionally, the VQI includes only a subset of hospitals providing vascular care and may not be fully representative of national practice patterns. Related to this, we cannot comment on the intensity of medical therapy and exercise regimens, especially for patients without symptoms or claudication, to fully capture the practice variation for PAD. Finally, hypotheses can be drawn about the reasons for variation but without feedback from the providers and patients themselves, it is difficult to do more than speculate on the reasons for variation in practice. This analysis of variation is a step toward identifying opportunities for improving care, which will become increasingly important to address as we move toward basing reimbursement on performance.
Further analyses are necessary before we can reliably comment on what is appropriate or not beyond what has already been stated through the respective societal guidelines. It will also be important to identify which of these areas of variation lead to worse risk-adjusted outcomes to determine priority targets for quality improvement. This is beyond the scope of our current analysis but will be addressed in subsequent reports.
CONCLUSIONS
Within this national clinical dataset, there is wide variation in areas of known best practice, so called unwarranted variation, and even more variation in areas of clinical ambiguity, where further research is warranted, for the treatment of PAD. 
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